Last $27.52 USD
Change Today -1.80 / -6.14%
Volume 212.3K
PTLA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 11:13 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

portola pharmaceuticals inc (PTLA) Snapshot

Open
$29.12
Previous Close
$29.32
Day High
$29.12
Day Low
$26.83
52 Week High
07/3/14 - $31.48
52 Week Low
05/21/14 - $19.59
Market Cap
1.1B
Average Volume 10 Days
479.7K
EPS TTM
$-2.68
Shares Outstanding
41.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PORTOLA PHARMACEUTICALS INC (PTLA)

Related News

No related news articles were found.

portola pharmaceuticals inc (PTLA) Related Businessweek News

No Related Businessweek News Found

portola pharmaceuticals inc (PTLA) Details

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company’s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes that regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. The company was founded in 2003 and is headquartered in South San Francisco, California.

70 Employees
Last Reported Date: 03/3/14
Founded in 2003

portola pharmaceuticals inc (PTLA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $575.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $415.5K
Executive Vice President of Research & Develo...
Total Annual Compensation: $463.3K
Compensation as of Fiscal Year 2013.

portola pharmaceuticals inc (PTLA) Key Developments

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-a Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Portola Pharmaceuticals, Inc. announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. Andexanet alfa was well tolerated with no serious adverse events reported. Top-line efficacy data from the first of two ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors -- Apixaban) studies demonstrated that an intravenous (IV) bolus of andexanet alfa immediately and significantly reversed the anticoagulation activity of Bristol-Myers Squibb Company and Pfizer Inc.'s direct Factor Xa inhibitor Eliquis (apixaban).

Portola Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:55 PM

Portola Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:55 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: William Lis, Chief Executive Officer and Director.

Portola Pharmaceuticals, Inc. Announces Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Portola Pharmaceuticals, Inc. announced unaudited earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported collaboration and license revenue of $2,415,000, loss from operations of $31,505,000, net loss attributable to common stockholders of $31,350,000 or $0.76 basic and diluted per share, compared to the collaboration and license revenue of $2,601,000, loss from operations of $21,940,000, net loss attributable to common stockholders of $21,598,000 or $1.47 basic and diluted per share, for the same quarter a year ago. For the year to date, the company reported collaboration and license revenue of $4,786,000, loss from operations of $62,529,000, net loss attributable to common stockholders of $62,076,000 or $1.51 basic and diluted per share, compared to the collaboration and license revenue of $5,709,000, loss from operations of $39,594,000, net loss attributable to common stockholders of $39,741,000 or $4.92 basic and diluted per share, for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTLA:US $27.52 USD -1.80

PTLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTLA.
View Industry Companies
 

Industry Analysis

PTLA

Industry Average

Valuation PTLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 125.8x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 102.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PORTOLA PHARMACEUTICALS INC, please visit www.portola.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.